Pediatric Rheumatology

, 6:P237 | Cite as

Effective use of rituximab in combination with low dose cyclophosphamide in childhood onset systemic lupus erythematosus (SLE) with relapsing class IV nephritis

  • PM Miettunen
  • LA Hamiwka
  • AW Wade
  • JP Midgley
  • S Grisaru
Open Access
Poster presentation
  • 943 Downloads

Keywords

Systemic Lupus Erythematosus Nephritis Mycophenolate Mofetil Systemic Lupus Erythematosus Activity Renal Flare 

Objectives

We evaluated effectiveness of rituximab, an anti-CD20 monoclonal antibody, in combination with low dose cyclophosphamide and intravenous (IV) methylprednisolone in three pediatric SLE patients with relapsing class IV nephritis.

Methods

Patients 1 and 2

Identical twin females with SLE, complicated by biopsy proven class IV nephritis at age 6-years and treated with NIH cyclophosphamide protocol (NIHCP), had biopsy documented Class IV renal flare at age 10-years; unresponsive to mycophenolate mofetil (MMF) and corticosteroids.

Patient 3

A 12-year old female with SLE, complicated by biopsy documented Class IV nephritis and treated with NIHCP, had 2 further renal flares, which responded to a cumulative dose of 36 grams of cyclophosphamide. At age 16, she had another biopsy documented class IV renal flare, despite maintenance with MMF.

All patients received pulse therapy with: IV cyclophosphamide 0.5 g/m2 with IV methylprednisolone (IVMP) 250 mg on days 1 and 23; IV rituximab 375 mg/m2 on days 2, 9, 16 and 23.

Results

All 3 patients had a dramatic improvement in urine protein-creatinine ratios, and normalization of blood pressure. Despite low-dose daily corticosteroids, all patients had an increase in generalized SLE activity by 4 weeks following rituximab therapy, which responded to re-introduction of MMF. No side effects apart from expected decrease in B-cell counts were noted.

Conclusion

Rituximab in combination with low dose cyclophosphamide and IVMP was effective in controlling recurrent class IV nephritis in 3 pediatric SLE patients.

Re-introduction of mycophenolate mofetil was required within 4 weeks following rituximab therapy to maintain disease remission.

Copyright information

© Miettunen et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Authors and Affiliations

  • PM Miettunen
    • 1
  • LA Hamiwka
    • 1
  • AW Wade
    • 1
  • JP Midgley
    • 1
  • S Grisaru
    • 1
  1. 1.University of CalgaryCalgaryCanada

Personalised recommendations